Other outcomes
tumor necrosis
TUMOR NECROSIS
The 7-point SMBG was measured immediately before breakfast, lunch, and dinner, two hours after each meal, and at bedtime, at week 0, 4, 12 and 20. In the TENS group, the 7-point SMBG maintained relatively more stable GV compared to the placebo group, as reflected by the significant difference of MAGE at week 20 between the TENS group and the placebo (66 (33) mg/dL [95% CI 58, 73] vs. 79 (33) mg/dL [95% CI 72, 87]) (Table (Following 20 weeks of treatment, most subjects in the TENS and the placebo groups maintained stable OAD regimens in the maintenance period of the study. Overall, four subjects had OAD regimen change: two in the TENS group, and two in the placebo group (Supplementary Table Exploratory biomarkers including CRP, adiponectin, TNF-α, and FGF-21 were performed at week 0 and 20. Figure Change of exploratory parameters from before (week 0) and after (week 20) treatment in Transcutaneous Electrical Nerve Stimulator (TENS) vs. the placebo group. Statistical analysis with mixed model two–way ANOVA was carried out. Values are means ± standard error of mean (SEM), ns, non-significant. CRP, C-reactive protein; TNF-α, tumor necrosis factor-α; FGF-21, fibroblast growth factor-21.